Skip to content


Open Access

Uremia alters HDL composition and cholesterol efflux capacity

  • Michael Holzer1,
  • Ruth Birner-Grünberger2,
  • Tatjana Stojaković3,
  • Dalia El-Gamal1,
  • Veronika Binder1,
  • Christian Wadsack4,
  • Ákos Heinemann1 and
  • Gunther Marsche1Email author
BMC Pharmacology and Toxicology201213(Suppl 1):A15

Published: 17 September 2012


Renal DiseaseFunctional ImpairmentLipid CompositionCardiovascular MortalityUremia


Functional impairment of HDL may contribute to the excess cardiovascular mortality experienced by patients with renal disease, but the effect of advanced renal disease on the composition and function of HDL is not well understood.


Mass spectrometry and biochemical analyses were used to study alterations in the proteome and lipid composition of HDL isolated from patients on maintenance hemodialysis.


We identified a significant increase in the amount of acute-phase protein serum amyloid A1, albumin, lipoprotein-associated phospholipase A2, and apoC-III composing uremic HDL. Furthermore, uremic HDL contained reduced phospholipids and increased triglycerides and lysophospholipids. With regard to function, these changes impaired the ability of uremic HDL to promote cholesterol efflux from macrophages.


In summary, the altered composition of HDL in renal disease seems to inhibit the cardioprotective properties of HDL. Assessing HDL composition and function in renal disease may help to identify patients at increased risk for cardiovascular disease.



This work was supported by the Austrian Science Fund FWF (grants P21004-B02 and P22976-B18).

Authors’ Affiliations

Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria
Proteomics Core Facility, Centre for Medical Research, Medical University of Graz, Graz, Austria
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria


© Holzer et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.